RECORD // Company

Transcode Therapeutics, Inc.

Built 2026-11-22T05:04:07Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • TransCode Therapeutics · Ctgov · exact name match to 'Transcode Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • TRANSCODE THERAPEUTICS INC · Epa echo · same registered legal name as 'Transcode Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • TRANSCODE THERAPEUTICS INC · Epa echo · same registered legal name as 'Transcode Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • TRANSCODE THERAPEUTICS, INC. · USAspending · same registered legal name as 'Transcode Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001104659-26-128277

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-107,382,1783 months ended 2026-09-3010-Q2026-11-160001104659-26-1282772026-11-22 05:04 UTCReport an error
Interest expense$6,9793 months ended 2026-09-3010-Q2026-11-160001104659-26-1282772026-11-22 05:04 UTCReport an error
Cash and cash equivalents$4,635,839at 2026-09-3010-Q2026-11-160001104659-26-1282772026-11-22 05:04 UTCReport an error
Contract liabilities, current$0at 2026-09-3010-Q2026-11-160001104659-26-1282772026-11-22 05:04 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001829635
Ticker
RNAZ
EIN
811065054
CUSIP
89357L501
Record ID
sx:sec:0001829635

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
Business address6 LIBERTY SQUARE, #2382, BOSTON, MA, 021092026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 05:04 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-34,661,0762025-12-3110-K, XBRL NetIncomeLoss2026-11-22 05:04 UTCReport an error
Total assets (at 2025-12-31)$162,398,6892025-12-3110-K, XBRL Assets2026-11-22 05:04 UTCReport an error
Stockholders' equity (at 2025-12-31)$10,335,4662025-12-3110-K, XBRL StockholdersEquity2026-11-22 05:04 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$17,813,5212025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:04 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-19,516,2292025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:04 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$6,6602025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 05:04 UTCReport an error
Operating lease liabilities (at 2024-12-31)$38,2912024-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 05:04 UTCReport an error
Form D total offering amount (D filed 2024-12-12)$8,000,0002024-12-12D2026-11-22 05:04 UTCReport an error
Form D total amount sold (D filed 2024-12-12)$8,000,0002024-12-12D2026-11-22 05:04 UTCReport an error
Form D industry groupBiotechnology2024-12-12D2026-11-22 05:04 UTCReport an error
Form D revenue rangeNo Revenues2024-12-12D2026-11-22 05:04 UTCReport an error
Form D date of first sale2024-12-022024-12-12D2026-11-22 05:04 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-28)On October 28, 2026, TransCode Therapeutics, Inc. (the “Company”) issued a press release announcing that its board of directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.2026-10-28SEC EDGAR 8-K 0001104659-26-119658 (text as filed, excerpt)2026-11-22 05:04 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-01)As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”) dated as of April 6, 2026, pursuant to which the Company has the right to sell Yorkville up to $14 million of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). In connection with the SEPA, Yorkville also agreed to advance the Company up to $6.0 million, less certain amounts, to be paid in two tranches, in exchange for the…2026-10-01SEC EDGAR 8-K 0001104659-26-112826 (text as filed, excerpt)2026-11-22 05:04 UTCReport an error
8-K Item 2.04, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under (filed 2026-10-01)an Off-Balance Sheet Arrangement The information set forth in Item 1.01 of this Current Report is incorporated herein by reference. 22026-10-01SEC EDGAR 8-K 0001104659-26-112826 (text as filed, excerpt)2026-11-22 05:04 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-28)On September 28, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing updated clinical data from its Phase 1a dose clinical trial of TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.2026-09-28SEC EDGAR 8-K 0001104659-26-111170 (text as filed, excerpt)2026-11-22 05:04 UTCReport an error
Largest institutional holder #1 (13F as filed): Yorkville Advisors Global, LP$121,9582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$40,6442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD FIDUCIARY TRUST CO$18,5182026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #4 (13F as filed): UBS Group AG$17,9342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #5 (13F as filed): FMR LLC$4,3842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #6 (13F as filed): Tower Research Capital LLC (TRC)$4,2042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #7 (13F as filed): WELLS FARGO & COMPANY/MN$3422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error
Largest institutional holder #8 (13F as filed): SBI Securities Co., Ltd.$752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:04 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.